SCHEMBL4906517

SCHEMBL4906517

CC(C)NS(=O)(=O)c1ccc2c(c1)C(=NNc1ccccc1C(=O)NCc1ccccc1)C(=O)N2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 4/20 0.42
PTPN11 Q06124 2/20 0.42
MGAT2 Q10469 1/20 0.41
CCR1 P32246 2/20 0.41
KCNA5 P22460 1/20 0.40
ITGA4 P13612 1/20 0.39
ITGB7 P26010 1/20 0.39
MMP8 P22894 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 1/20 0.38
CDK2 P24941 1/20 0.37
KDR P35968 1/20 0.37
ADAMTS4 O75173 1/20 0.37
TUBB P07437 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NAMPT P43490 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4906515 1.00 KDM4E (0.43) KDM4EALDH1A1PTPN11MGAT2CCR1
SCHEMBL4906448 0.91 PTPN11 (0.54) KDM4EALDH1A1PTPN11MEN1KMT2A
SCHEMBL4906451 0.91 PTPN11 (0.54) KDM4EALDH1A1PTPN11MEN1KMT2A
SCHEMBL4908785 0.91 CDK2 (0.39) KDM4EALDH1A1PTPN11MGAT2CDK2
SCHEMBL4908777 0.91 CDK2 (0.39) KDM4EALDH1A1PTPN11MGAT2CDK2
SCHEMBL4903838 0.89 CDK2 (0.40) ALDH1A1PTPN11MGAT2KMT2ACDK2
SCHEMBL4903841 0.89 CDK2 (0.40) ALDH1A1PTPN11MGAT2KMT2ACDK2
SCHEMBL4903828 0.89 PTPN11 (0.43) KDM4EALDH1A1PTPN11MGAT2MEN1
SCHEMBL4903823 0.89 PTPN11 (0.43) KDM4EALDH1A1PTPN11MGAT2MEN1
SCHEMBL14111974 0.88 PTPN11 (0.52) KDM4EALDH1A1PTPN11MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987474-B2 Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs UNIVERSITY OF SOUTH FLORIDA (US) 2015-03-24 US disclosed
US-20080176309-A1 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer UNIVERSITY OF SOUTH FLORIDA (US) 2008-07-24 US disclosed
WO-2007117699-A2 INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS UNIVERSITY OF SOUTH FLORIDA (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176309-A1 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer PTPN7, PTPN1, PTPN2 KDM4E 3476/4885ALDH1A1 3859/4885PTPN11 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.